This analysis investigates the prevalence of financial relationships between oncologist authors of clinical drug trials and the pharmaceutical industry and how often such financial interests are unreported.
No takes yet. Share an insight, caveat, or question.
Wayant et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: